摘要
目的:评价联合吸入噻托溴铵和布地奈德福莫特罗对中重度稳定期慢性阻塞性肺疾病(chronic obstructive pulmonary disease COPD)患者的疗效。方法:72例中重度稳定期COPD患者按照随机数字表法分为2组:(1)治疗组37例(男30例,女7例),吸入布地奈德福莫特罗160/4.5μg每次2吸每日2次,同时吸入噻托溴铵干粉胶囊1粒(18μg),每日1次;(2)对照组35例(男29例,女6例),吸入布地奈德福莫特罗160/4.5μg,每次2吸每日2次。观察患者治疗前、治疗后4、16、24W运动耐量、呼吸困难评分、肺功能的变化。结果:治疗4、16、24W后两组患者6min步行距离(6MWD)、FEV1和FVC均较治疗前明显增加,呼吸困难评分(MMRC)、RV均较治疗前明显下降(P<0.05),且治疗组各项指标改善明显优于对照组(P<0.05)。结论:噻托溴铵联合布地奈德福莫特罗治疗中重度稳定期COPD优于单独吸入布地奈德福莫特罗治疗。
Objective:To observe the efficacy of combining tiotropium and budesonide/formoterol in patients with moderate-to-severe stable chronic obstructive pulmonary disease(COPD).Methods:Seventy-two patients received 24 weeks of treatment randomly in one of the two treatment groups:(1) budesonide/formoterol 160 /4.5μg twice daily and tiotropium 18μg once daily(n = 37,M/F:30 /7) ;(2) budesonide/formoterol twice daily(n = 35,M/F:29 /6) ;The exercise tolerance,dyspnea score and lung function were measured before and 4,16,24 weeks after the treatment respectively.Results:4,16,24 weeks after the treatment respectively,6 minute walk test,FEV1,FVC had improved significantly above baseline,And in the combination group after the trial was significantly improved compared to that budesonide/formoterol alone.The dyspnea score of medical research council scale(MRC),RV in both groups had decreased significantly under baseline.And in the combination group after the trial was significantly increased compared to that budesonide/formoterol alone.Conclusion:Combination therapy with tiotropium and budesonide/formoterol may provide benefits in patients with moderate-to-severe stable COPD as compared to budesonide/formoterol alone in the treatment of COPD.
出处
《黑龙江医药》
CAS
2012年第5期817-819,共3页
Heilongjiang Medicine journal
